drugset / Trial / NCT05615012

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

NCT05615012

Phase 1 Completed 76 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelTreatment

Summary

The aim of this study is to assess the effect of coadministration of multiple oral doses of BMS-986322 with rosuvastatin, metformin, and methotrexate in healthy participants.

Timeline

Start
2022-11-11
Primary completion
2023-12-13
Completion
2023-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject LOMECITINIB Small molecule
Subject Metformin Small molecule
Subject Methotrexate Small molecule
Subject Rosuvastatin Small molecule
Background Leucovorin Small molecule

Indications

No indication recorded.